- Home
- PPBT vs RAYA Comparison
PPBT vs RAYA Comparison
Compare PPBT & RAYA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PPBT
- RAYA
- Stock Information
- Founded
- PPBT 2010
- RAYA 2019
- Country
- PPBT Israel
- RAYA China
- Employees
- PPBT N/A
- RAYA N/A
- Industry
- PPBT Biotechnology: Pharmaceutical Preparations
- RAYA Metal Fabrications
- Sector
- PPBT Health Care
- RAYA Consumer Discretionary
- Exchange
- PPBT Nasdaq
- RAYA Nasdaq
- Market Cap
- PPBT 5.5M
- RAYA 5.2M
- IPO Year
- PPBT N/A
- RAYA 2022
- Fundamental
- Price
- PPBT $0.59
- RAYA $5.03
- Analyst Decision
- PPBT Strong Buy
- RAYA
- Analyst Count
- PPBT 1
- RAYA 0
- Target Price
- PPBT $33.00
- RAYA N/A
- AVG Volume (30 Days)
- PPBT 234.5K
- RAYA 198.0K
- Earning Date
- PPBT 11-14-2025
- RAYA 01-01-0001
- Dividend Yield
- PPBT N/A
- RAYA N/A
- EPS Growth
- PPBT N/A
- RAYA N/A
- EPS
- PPBT N/A
- RAYA N/A
- Revenue
- PPBT N/A
- RAYA $30,300,360.00
- Revenue This Year
- PPBT N/A
- RAYA $20.95
- Revenue Next Year
- PPBT N/A
- RAYA N/A
- P/E Ratio
- PPBT N/A
- RAYA N/A
- Revenue Growth
- PPBT N/A
- RAYA 49.10
- 52 Week Low
- PPBT $0.53
- RAYA $3.65
- 52 Week High
- PPBT $13.95
- RAYA $737.00
- Technical
- Relative Strength Index (RSI)
- PPBT 29.54
- RAYA 55.61
- Support Level
- PPBT $0.56
- RAYA $4.69
- Resistance Level
- PPBT $0.66
- RAYA $6.14
- Average True Range (ATR)
- PPBT 0.04
- RAYA 0.63
- MACD
- PPBT 0.05
- RAYA -0.27
- Stochastic Oscillator
- PPBT 29.11
- RAYA 13.57
About PPBT Purple Biotech Ltd.
Purple Biotech Ltd is a clinical-stage company focused on advancing first-in-class therapies to overcome tumor immune evasion and drug resistance, and to create treatments for people with cancer. Its oncology pipeline includes NT219: A dual inhibitor, small molecule that simultaneously targets Insulin Receptor Substrate 1 and 2 (IRS1/2) and Signal Transducer and Activator of Transcription (STAT3), two survival signal transduction pathways driving the development of cancer drug resistance. and CM24: is a humanized monoclonal antibody designed to block the interactions of Carcinoembryonic Antigen Related Cell Adhesion Molecule 1 (CEACAM1), a glycoprotein that plays a key role in immune regulation, cell adhesion, and tumor progression, CAPTN3.
About RAYA Erayak Power Solution Group Inc.
Erayak Power Solution Group Inc engages in manufacturing, research and development, and wholesale and retail of power solution products. Its product portfolio includes sine wave and off-grid inverters, inverter and gasoline generators, battery, and smart chargers, and custom-designed products. It derives the majority revenue from four products namely inverters, chargers, power bank, and gasoline generators. The company generates the majority of its revenue from Inverters. The company geographically operates in China, Australia, Poland, U.K., and Germany. It derives maximum revenue from China.